A phase 1b open-label dose-finding study of ustekinumab in young adults with type 1 diabetes.
Ashish K MarwahaSamuel ChowAnne M PesenackerLaura CookAnnika SunS Alice LongJennie Hsiu Mien YangKirsten A Ward-HartstongeEvangelia WilliamsClara Domingo-VilaKhalif HalaniKristina M HarrisTimothy I M TreeMegan K LevingsThomas ElliottRusung TanJan P DutzPublished in: Immunotherapy advances (2021)
Ustekinumab was deemed safe to progress to efficacy studies by the DSMB at doses used to treat psoriasis in adults with T1D. A 90 mg maintenance dosing schedule reduced proinsulin-specific IFN-γ and IL-17A-producing T cells. Further studies are warranted to determine if ustekinumab can prevent C-peptide AUC decline and induce a clinical response.